|
Chronic kidney disease stage 5
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Mean FGF-23 levels increased markedly as time before ESKD decreased, while PTH and phosphate levels increased modestly and calcium levels declined minimally.
|
31668375 |
2020 |
|
Chronic kidney disease stage 5
|
0.300 |
Biomarker
|
disease |
BEFREE |
We therefore determined vertebral fracture prevalence and incidence in ESRD patients and assessed associations of vertebral trabecular bone mineral density (BMD) and PTH with vertebral fracture.
|
31728605 |
2020 |
|
Chronic kidney disease stage 5
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Renal hyperparathyroidism is a common complication of chronic kidney disease (CKD) or end-stage renal disease (ESRD) characterized by elevated parathyroid hormone levels secondary to derangements in the homeostasis of calcium, phosphate, and vitamin D. Rapid correction of severe and prolonged hyperparathyroidism by surgical parathyroidectomy in long-term hemodialysis patients occasionally causes hungry bone syndrome.
|
30691427 |
2019 |
|
Chronic kidney disease stage 5
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Current treatment strategies focus on correcting abnormal calcium, phosphate, parathyroid hormone, and vitamin D levels in ESRD patients.
|
30991406 |
2019 |
|
Chronic kidney disease stage 5
|
0.300 |
Biomarker
|
disease |
BEFREE |
A literature search was conducted using MEDLINE, EMBASE, and Cochrane Database from inception through November 2017 to identify studies evaluating incidence of denosumab-associated hypocalcemia and changes in serum calcium, phosphate, alkaline phosphatase (ALP), parathyroid hormone (PTH), and BMD from baseline to post-treatment course of denosumab in ESRD patients.
|
29713798 |
2018 |
|
Chronic kidney disease stage 5
|
0.300 |
Biomarker
|
disease |
BEFREE |
This study examined the features of different PTH fragments in stage 5 chronic kidney disease (CKD) and the effects of parathyroidectomy (PTX) on the above markers in severe secondary hyperparathyroidism (SHPT) patients.
|
30223287 |
2018 |
|
Chronic kidney disease stage 5
|
0.300 |
Biomarker
|
disease |
BEFREE |
Although current treatment strategies focus on correcting abnormal calcium, phosphate, parathyroid hormone, or vitamin D levels in ESRD patients, a better understanding of the mechanisms of abnormal tissue calcification may lead to the development of new therapeutic agents that are capable of reducing vascular calcification and improving the cardiovascular outcome of ESRD patients.
|
30041207 |
2018 |
|
Chronic kidney disease stage 5
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Patients with end-stage renal disease (ESRD) who received parathyroidectomy (PTX) had persistently reduced levels of parathyroid hormone.
|
27790808 |
2018 |
|
Chronic kidney disease stage 5
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, recent translational work has provided compelling evidence for a causal role of parathyroid hormone (PTH) in the pathogenesis of adipose tissue browning and increased energy expenditure, a critical component of PEW in ESRD.
|
29707907 |
2018 |
|
Chronic kidney disease stage 5
|
0.300 |
Biomarker
|
disease |
BEFREE |
The KIM-1 in HF (+) CKD5-HD patients was found to correlate with PTH ( P = .043, R = -.36) and 25-OH vitamin D ( P = .037, R = .36).
|
28990414 |
2018 |
|
Chronic kidney disease stage 5
|
0.300 |
Biomarker
|
disease |
BEFREE |
FGF 23, PTH and vitamin D status in end stage renal disease patients affected by VDR FokI and BsmI variants.
|
29458003 |
2018 |
|
Chronic kidney disease stage 5
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The cytologic and histologic findings, in correlation with the clinical history, radiographic features, markedly increased parathyroid hormone levels and other serologic studies, were diagnostic of the reactive lesion seen in brown tumor of hyperparathyroidism secondary to chronic renal failure.
|
29193813 |
2018 |
|
Chronic kidney disease stage 5
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Stepwise regression analysis was applied to estimate the relationships between network efficiency and blood biochemistry level (urea, creatine, phosphate, Ca<sup>2+</sup>, hematocrit, cystatin, hemoglobin levels, parathyroid hormone, K<sup>+</sup> and Na<sup>+</sup>), and only the hematocrit level was significantly associated with global efficiency in patients with ESRD.
|
29063504 |
2018 |
|
Chronic kidney disease stage 5
|
0.300 |
Biomarker
|
disease |
BEFREE |
PTH-dependent hypercalcemia is usually caused by parathyroid tumors, which may give rise to primary hyperparathyroidism (PHPT) or tertiary hyperparathyroidism, which usually arises in association with chronic renal failure and in the treatment of hypophosphatemic rickets.
|
28914984 |
2017 |
|
Chronic kidney disease stage 5
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, high PTH levels and disorders of mineral metabolism are associated with decreased heart rate variability in ESRD patients.
|
28243964 |
2017 |
|
Chronic kidney disease stage 5
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
A 32-year-old Hispanic male with end-stage renal disease on peritoneal dialysis underwent successful surgical parathyroidectomy (intact parathyroid hormone level: 2,328pg/mL; postsurgical: 287-69pg/mL [normal: 8.5-72.5]).
|
28104108 |
2017 |
|
Chronic kidney disease stage 5
|
0.300 |
Biomarker
|
disease |
RGD |
Two novel vitamin D receptor modulators with similar structures exhibit different hypercalcemic effects in 5/6 nephrectomized uremic rats.
|
23548814 |
2013 |
|
Chronic kidney disease stage 5
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The highly increased PTH levels that can be observed in chronic renal failure might be one contributor for the elevated sympathetic nerve activity and the associated cardiovascular mortality in patients with end stage renal disease.
|
21756942 |
2011 |
|
Chronic kidney disease stage 5
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The results of clinical trials with cinacalcet hydrochloride, a second generation calcimimetic compound, have shown that calcimimetics possess lowering effects not only on serum PTH levels but also on serum calcium x phosphorus product levels, a hallmark of an increased risk for cardiovascular death in dialysis patients with end-stage renal disease (ESRD).
|
15781990 |
2005 |
|
Chronic kidney disease stage 5
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Association between vitamin D receptor FokI. Polymorphism and serum parathyroid hormone level in patients with chronic renal failure.
|
15887856 |
2005 |
|
Chronic kidney disease stage 5
|
0.300 |
Biomarker
|
disease |
BEFREE |
Chronic renal failure influences a number of factors that cause accelerated atherogenesis, with calcium, phosphorus, and PTH playing key roles.
|
12753279 |
2003 |
|
Chronic kidney disease stage 5
|
0.300 |
Biomarker
|
disease |
BEFREE |
The purpose of this research was to characterize CYP2D6, GST-M1 and GST-T1 enzyme expression in human parathyroid tissue, and to determine whether or not there is any association between deficiencies in these enzymes and serum parathyroid hormone concentrations in patients with end-stage renal disease.
|
12848777 |
2003 |
|
Chronic kidney disease stage 5
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure.
|
11012879 |
2000 |
|
Chronic kidney disease stage 5
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
To investigate whether the down-regulation of renal parathyroid hormone/parathyroid hormone related protein (PTH/PTHrP) receptor messenger ribonucleic acid (mRNA) expression is a general phenomenon in patients with different stages of renal disease, besides chronic renal failure.
|
10322647 |
1998 |
|
Chronic kidney disease stage 5
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Adynamic bone disease unrelated to aluminum deposition, with low parathyroid hormone (PTH) levels, has increased in patients with end-stage renal failure.
|
9740163 |
1998 |